Personalized Tasty&Healthy whole-food diet for maintaining remission in children and adults with Crohn's disease: results from the MyTasty open-label trial

被引：0

作者：

Plotkin, L. ^{[1
,2
]}

Frutkoff, Y. Aharoni ^{[1
]}

Shavit, Z. ^{[1
]}

Focht, G. ^{[1
]}

Livovsky, J. ^{[1
]}

Buchuk, R. ^{[1
]}

Lev-Zion, R. ^{[1
]}

Ledder, O. ^{[1
]}

Assa, A. ^{[1
]}

Boneh, R. Sigall ^{[3
]}

Weiss, B. ^{[4
]}

Slae, M. ^{[5
]}

Dotan, I ^{[6
]}

Kierkus, J. ^{[7
]}

Broide, E. ^{[8
]}

Griffiths, A. ^{[9
]}

Naftali, T. ^{[10
]}

Aloi, M. ^{[11
]}

Yerushalmy-Feler, A. ^{[12
]}

Schwerd, T. ^{[13
]}

Reifen, R. ^{[2
]}

Turner, D. ^{[1
]}

机构：

[1] Shaare Zedek Med Ctr, Juliet Keidan Inst Pediat Gastroenterol & Nutr, Jerusalem, Israel

[2] Hebrew Univ Jerusalem, Inst Biochem Food Sci, Nutr Robert H Smith Fac Agr Food & Environm, Rehovot, Israel

[3] E Wolfson Med Ctr, Pediat Gastroenterol & Nutr Unit, Holon, Israel

[4] Sheba Med Ctr, Pediat Gastroenterol, Ramat Gan, Israel

[5] Pediat Gastroenterol Ctr, Hadassah Ein Kerem, Jerusalem, Israel

[6] Rabin Med Ctr, Div Gastroenterol, Petah Tiqwa, Israel

[7] Childrens Mem Hlth Inst, Pediat Gastroenterol Unit, Warsaw, Poland

[8] Assaf Harofeh Med Ctr, Pediat Gastroenterol Unit, Zerifin, Israel

[9] Hosp Sick Children, Pediat Gastroenterol, Toronto, ON, Canada

[10] Meir Hosp, Gastroenterol, Kefar Sava, Israel

[11] Sapienza Univ Rome, Dept Pediat Gastroenterol, Rome, Italy

[12] Tel Aviv Sourasky Med Ctr, Pediat Gastroenterol, Tel Aviv, Israel

[13] LMU Munchen, Dr Hauner Childrens Hosp, Munich, Germany

来源：

JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷

关键词：

D O I：

10.1093/ecco-jcc/jjae190.1267

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P1093

引用

页码：i2009 / i2010

页数：2

共 50 条

[31] Microbiome composition determines sustained remission after the Crohn's Disease Exclusion Diet (CDED) with or without Partial Enteral Nutrition in adults with mild-moderate Crohn's disease; Results from the CDED-AD Pilot Randomized Controlled Trial
Sigall-Boneh, R.
Organ, S.
Yanai, H.
Maharshak, N.
Dotan, I.
Abramas, L.
Wine, E.
Widesma, N.
Gu, H.
Bielawski, J.
Dunn, K.
Van Limbergen, J.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I2134 - I2134
[32] LONG-TERM SAFETY AND EFFICACY OF RISANKIZUMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE: FINAL RESULTS FROM THE PHASE 2 OPEN-LABEL EXTENSION STUDY
Ferrante, Marc
Feagan, Brian G.
Panes, Julian
Baert, Filip J.
Louis, Edouard
Dewit, Olivier
Kaser, Arthur
Duan, Weijiang
Gustafson, Dawn
Liao, Xiaomei
Wallace, Kori
Kalabic, Jasmina
D'Haens, Geert R.
GASTROENTEROLOGY, 2020, 158 (06) : S1198 - S1198
[33] Long-term safety and efficacy of risankizumab treatment in patients with Crohn's disease: Final results from the Phase 2 open-label extension study
Ferrante, M.
Feagan, B. G.
Panes, J.
Baert, F.
Louis, E.
Dewit, O.
Kaser, A.
Duan, W. R.
Gustafson, D.
Liao, X.
Wallace, K.
Kalabic, J.
D'Haens, G. R.
JOURNAL OF CROHNS & COLITIS, 2020, 14 : S024 - S025
[34] Precise infliximab exposure and pharmacodynamic control to achieve deep remission in paediatric Crohn's disease (REMODEL-CD): study protocol for a multicentre, open-label, pragmatic clinical trial in the USA
Minar, Phillip Paul
Colman, Ruben J.
Zhang, Nanhua
Mizuno, Tomoyuki
Vinks, Alexander A.
BMJ OPEN, 2024, 14 (03):
[35] NOVEL FORMULATION OF CT-P13 (INFLIXIMAB BIOSIMILAR) FOR SUBCUTANEOUS ADMINISTRATION: INITIAL RESULTS FROM A PHASE I OPEN-LABEL RANDOMIZED CONTROLLED TRIAL IN PATIENTS WITH ACTIVE CROHN'S DISEASE
Schreiber, Stefan
Jang, Byung Ik
Borzan, Vladimir
Lahat, Adi
Pukitis, Aldis
Osipenko, Marina
Mostovoy, Yuriy
Ben-Horin, Shomron
Ye, Byong Duk
Lee, Sang Joon
Lee, Sung Young
Kim, Mi Rim
Reinisch, Walter
GASTROENTEROLOGY, 2018, 154 (06) : S1371 - S1371
[36] An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity Results From a Pragmatic Open-Label Trial
Tran-Duy, An
Ghiti Moghadam, Marjan
Voshaar, Martijn A. H. Oude
Vonkeman, Harald E.
Boonen, Annelies
Clarke, Philip
McColl, Geoff
ten Klooster, Peter M.
Zijlstra, T. R.
Lems, Willem F.
Riyazi, N.
Griep, E. N.
Hazes, J. M. W.
Landewe, Robert
Bernelot Moens, Hein J.
van Riel, Piet L. C. M.
van de Laar, Mart A. F. J.
Jansen, T. L.
ARTHRITIS & RHEUMATOLOGY, 2018, 70 (10) : 1557 - 1564
[37] Rapid onset of response and remission to subcutaneous certolizumab pegol and lack of influence of concomitant baseline medications in active Crohn disease: Results from the open-label induction phase of the precise 2 study
Thomsen, Ole O.
Screiber, Stefan
Khaliq-Kareemi, Munaa
Hanauer, Stephen B.
Bloomfield, Ralph
Sandborn, William J.
GASTROENTEROLOGY, 2007, 132 (04) : A505 - A505
[38] CCX 282-b, an oral CCR9-specific antagonist, induces high levels of remission in the open-label phase of protect-1 clinical trial in crohn's disease
Hetzel, D. J.
Gibson, P. R.
Radford-Smith, G.
Macrae, F.
Bekker, P.
Schall, T. J.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 : A190 - A190
[39] Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease With 3 Years of Treatment: Results From the FORTIFY Open-Label Long-Term Extension
Ferrante, M.
Panaccione, R.
Colombel, J. F.
Dubinsky, M. C.
Hisamatsu, T.
Lindsay, J. O.
Song, A.
Yao, Y.
Zhang, Y.
Zambrano, J.
Aponte, F.
Duan, W. R.
D'Haens, G.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i109 - i111
[40] Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease: Results From the One-Year SEQUENCE Open-Label Long-Term Extension
Peyrin-Biroulet, L.
Atreya, R.
Danese, S.
Lindsay, J. O.
Chapman, J. C.
Anschutz, T.
Huang, X.
Zambrano, J.
Platt, A.
Joshi, N.
Cross, R. K.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1407 - i1409

← 1 2 3 4 5 →